Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xubo, Zhang, Yi, He, Xin, Moloudizargari, Milad, Yu, Teng, Wang, Lin, Liu, Weiwei, Jin, Lan, Xu, Huiying, Xu, Yang, Tao, Zhihua, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314591/
https://www.ncbi.nlm.nih.gov/pubmed/37391809
http://dx.doi.org/10.1186/s40164-023-00424-z
_version_ 1785067341668679680
author Gong, Xubo
Zhang, Yi
He, Xin
Moloudizargari, Milad
Yu, Teng
Wang, Lin
Liu, Weiwei
Jin, Lan
Xu, Huiying
Xu, Yang
Tao, Zhihua
Qian, Wenbin
author_facet Gong, Xubo
Zhang, Yi
He, Xin
Moloudizargari, Milad
Yu, Teng
Wang, Lin
Liu, Weiwei
Jin, Lan
Xu, Huiying
Xu, Yang
Tao, Zhihua
Qian, Wenbin
author_sort Gong, Xubo
collection PubMed
description Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.
format Online
Article
Text
id pubmed-10314591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103145912023-07-02 Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting Gong, Xubo Zhang, Yi He, Xin Moloudizargari, Milad Yu, Teng Wang, Lin Liu, Weiwei Jin, Lan Xu, Huiying Xu, Yang Tao, Zhihua Qian, Wenbin Exp Hematol Oncol Correspondence Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment. BioMed Central 2023-06-30 /pmc/articles/PMC10314591/ /pubmed/37391809 http://dx.doi.org/10.1186/s40164-023-00424-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Gong, Xubo
Zhang, Yi
He, Xin
Moloudizargari, Milad
Yu, Teng
Wang, Lin
Liu, Weiwei
Jin, Lan
Xu, Huiying
Xu, Yang
Tao, Zhihua
Qian, Wenbin
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title_full Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title_fullStr Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title_full_unstemmed Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title_short Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
title_sort venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ash annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314591/
https://www.ncbi.nlm.nih.gov/pubmed/37391809
http://dx.doi.org/10.1186/s40164-023-00424-z
work_keys_str_mv AT gongxubo venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT zhangyi venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT hexin venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT moloudizargarimilad venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT yuteng venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT wanglin venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT liuweiwei venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT jinlan venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT xuhuiying venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT xuyang venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT taozhihua venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting
AT qianwenbin venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting

Ejemplares similares